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Abstract: Magnetite nanoparticles (MNPs) coated by branched poly (ethylene-imine) (PEI) were
synthesized in a one-pot. Three molecular weights of PEI were tested, namely, 1.8 kDa (sample
MNP-1), 10 kDa (sample MNP-2), and 25 kDa (sample MNP-3). The MNP-1 particles were further
functionalized with folic acid (FA) (sample MNP-4). The four types of particles were found to behave
magnetically as superparamagnetic, with MNP-1 showing the highest magnetization saturation.
The particles were evaluated as possible hyperthermia agents by subjecting them to magnetic fields
of 12 kA/m strength and frequencies ranging between 115 and 175 kHz. MNP-1 released the
maximum heating power, reaching 330 W/g at the highest frequency, in the high side of reported
values for spherical MNPs. In vitro cell viability assays of MNP-1 and MNP-4 against three cell
lines expressing different levels of FA receptors (FR), namely, HEK (low expression), and HeLa (high
expression), and HepG2 (high expression), demonstrated that they are not cytotoxic. When the cells
were incubated in the presence of a 175 kHz magnetic field, a significant reduction in cell viability
and clone formation was obtained for the high expressing FR cells incubated with MNP-4, suggesting
that MNP-4 particles are good candidates for magnetic field hyperthermia and active targeting.
Keywords: alternating magnetic field; cell viability; folic acid; magnetic hyperthermia; magnetite;
poly(ethylene-imine); nanotoxicity
1. Introduction
Cancer remains one of the most challenging diseases, its treatment involving, when
possible, a combination of surgical resection of the tumor with radiation therapy, chemother-
apy, and/or immunotherapy. However, this approach does not guarantee the complete
eradication of the cancer, and it is not exempt from risk since normal tissues are also dam-
aged. Alternative therapies are in demand, and the long-known positive effects of thermal
therapy on cancer has gained attention. The efficiency of the thermal treatment is depen-
dent on both the magnitude and the extent of the temperature increment [1,2]. The range of
41–48 ◦C is the so-called relevant temperature range suitable for hyperthermia treatments.
The underlying biological processes induced by hyperthermia are not fully understood
and the differential thermal sensitivity of tumor cells remains controversial [3–6], despite
the efforts dedicated to study the mechanism of the cellular effects [7]. Protein denaturation
starts at 39 ◦C, and at 40 ◦C, cells enter into an inactivation process that lasts for several
hours; the surviving cells reach a temporary thermotolerance that is overcome when
the temperature rises to 41–42 ◦C for several hours [8]. Severe hyperthermia treatments
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(43–45 ◦C) provoke oxidative stress, and irreversible injury occurs when the temperature
reaches values above 48 ◦C for a period of time exceeding a few minutes [1].
While tumor ablation is feasible, hyperthermia is generally implemented in the context
of cancer treatment at moderate temperatures (41–42 ◦C) as part of a combined therapy,
and its effect is the modification of the response to some drugs and/or sensitivity to
X-ray irradiation, increasing the efficiency of the traditional treatments and reducing their
side effects [9,10]. Regardless of the final temperature reached, hyperthermia implies the
heating of specific areas and the production of well-defined hot spots. In this context,
nanotechnology offers alternatives that are based on nanoparticles smaller than 100 nm
that are biocompatible and able to produce heat [2].
The proposed approach, known as magnetic fluid hyperthermia (MFHT), involves the
selective administration of MNPs and the exposition of the patient to an alternating magnetic
field (AMF), that provokes rotation of the particles (Brownian rotation) and rotation of the
magnetic moment in the particle (Neel’s rotation) with the concomitant heat generation [11,12].
Currently, several clinical trials are in progress for prostate cancer and glioblastoma [13], and
some have been reported, using licensed iron oxide nanoparticles (IONPs) and the medical
AMF device NanoActivator® (MagForce AG, Berlin, Germany) [13,14].
The limitations imposed by eddy currents and the fact that the implementation of
MNPs in therapy is affected by features such as shape, size, morphology, or dispersibility
have boosted the study of magnetic particles with this purpose [15]. In particular, su-
perparamagnetic iron oxide nanoparticles (SPIONs) have become the preferred materials
due to their relative ease of synthesis by coprecipitation, hydrothermal, pyrolysis, sol–gel,
microemulsion, sonochemical, electrodeposition, or polyol methods, as well as physical
ones [16]. However, they are prone to agglomeration and oxidation in the physiological en-
vironment, their fate in the human body being highly dependent on their surface properties.
Hence, surface modification is applied to improve their physicochemical and mechanical
properties and to control their surface activity, biocompatibility, and dispersibility. The
surface can be functionalized with organic or inorganic molecules, and the functional-
ization can be implemented during the synthesis or post -synthesis of the SPION. The
chemistry can be covalent, noncovalent, or be based on just sorption [16–19]. Among
the different modifications, those aimed at promoting the delivery of the particles to the
site of action are of paramount importance for localizing and optimizing the temperature
increase. The fact that the folic acid receptor (FR) is overexpressed in many cancers has led
to the investigation of the feasibility of using IONPs functionalized with folic acid (FA) for
receptor-mediated (or active) targeting [20–28].
Polyethyleneimine (PEI) is a commercial polymer widely used for different purposes,
from biocompatible coating of a surface to gene delivery [29–31]. It consists of repeating
units of amino groups spaced by two aliphatic carbons to yield a linear polymer of sec-
ondary amines or a branched polymer that contains primary, secondary, and tertiary amino
group. As a procedure for functionalizing MNPs, the solvothermal synthesis of Fe3O4
has been reported using PEI to prevent aggregation and decorate the MNP surface with
amino groups that are intended, for instance, (i) to reduce HAuCl4 and yield Fe3O4/Au
core shell [32–36], (ii) to prepare Yb3+ magnetic nanocomposites [37], (iii) as a coinitiator in
photopolymerization [37]. The use of amino groups with that purpose has been widely
described; for instance, Hanafy et al. [38] coated magnetite with PEG-bis amine for subse-
quent adsorption of carboxymethyl cellulose. The procedure proposed in the present work
has the advantage that the amino groups of PEI are incorporated during the synthesis and
not post-synthesis, likely yielding a more stable coating. This has also been done by other
authors, such as Felix et al. [36]. However, to the best of our knowledge, these particles
have not been studied from the perspective of their biomedical application and the surface
amino groups have not been exploited to incorporate targeting ligands. Such a study is
described in the present paper. Herein we report the synthesis and characterization of
Fe3O4-PEI nanoparticles, their covalent functionalization with FA, and the analysis of their
feasibility for MFHT. The results show that these particles provide excellent performance
Polymers 2021, 13, 1599 3 of 18
in MFHT in moderate magnetic fields and show low cytotoxicity, features which make
them suitable as a coadjutant in cancer treatment through hyperthermia.
2. Materials and Methods
2.1. Materials
The chemicals used for the synthesis were provided by Sigma-Aldrich (Darmstadt,
Germany) (PEI2K, PEI10K, PEI25K, DCC, Cl3Fe·6H2O, ethane-1,2-diol, folic acid), and
Scharlau (Barcelona, Spain) (anhydrous DMF, anhydrous pyridine, sodium acetate), and
they were used as received. Water used in the experiments was deionized and filtered in a
Milli-Q Academic, Millipore (Molsheim, France) system.
2.2. Methods
The synthesis of the particles was performed as described by Wang et al. [35]. Branched
PEI with molecular weights of 1.8 kDa (PEI2K), 10 kDa (PEI10K), and 25 kDa (PEI25K),
and containing primary, secondary, and tertiary amino groups were used, yielding samples
MNP-1, MNP-2, and MNP-3, respectively. An amount of 1 g of FeCl3·6H2O, 2 g of
branched PEI and 2 g of sodium acetate, and 60 mL of ethane-1,2-diol was sonicated for
30 min and then stored overnight at 40 ◦C. After a new sonication for 30 min, the sample
was heated at 60 ◦C under stirring for 1 h. Next, the sample was sealed in a 125 mL acid
digestion vessel and incubated in an oven at 200 ◦C for 10 h. Then, nanoparticles were
separated with the help of a permanent magnet, redispersed in deionized water, and dried
at 60 ◦C under vacuum (300 mbar). The functionalization with FA (sample MNP-4) was
carried out in one pot (see Scheme 1) and protected from light. An amount of 0.2 mmol of
FA was reacted in 1.2 mmol of N,N′-dicyclohexylcarbodiimide (DCC) in 7.5 mL of DMF:
pyridine (5:1) for 30 min to yield folic acid anhydride [39]. Then, 90 mg of nanoparticles
were added to the reaction that, after sonication, was were allowed to proceed at room
temperature for 19 h. Nanoparticles were washed thoroughly, first with methanol, and
then with ether and dried in air, protected from light.




Scheme 1. The process of linking folic acid (FA, bottom left) to the magnetite nanoparticles (bot-
tom, right). FA was reacted with N,N′-dicyclohexylcarbodiimide (EDC)/dimethyl formamide-
pyridine (DMF-Py), and the resulting anhydride was contacted with PEI-coated magnetite (top). 
Magnetic hyperthermia was applied to samples contained in 1.5 mL Eppendorf 
tubes, which were located inside a coil (8 turns, 45 mm coil length, 20 mm inner diameter) 
built with a copper tube of 6 mm inner diameter. Thermostatic water was circulated 
through the tube during the experiment, in order to avoid interference of Joule heating on 
the hyperthermia induced by the AMF. A Royer-type oscillator was used to produce the 
alternating current applied to the coil for producing the AMF. The frequencies used were 
115, 135, 155, and 175 kHz, and the H field amplitude was 12 kA/m in all cases, as deter-
mined with a NanoScience Laboratories Ltd. Probe (Keele, UK). The tube containing the 
suspension (0.5 mL and 10 mg/mL particle concentration) was pre-thermostated to the 
starting temperature of 30 °C and placed inside the coil. An optical fiber thermometer 
(Optocon AG, Weidmann Technologies Deutschland GMBH, Dresden, Germany) was 
used to measure the temperature of the sample at 3 s time intervals after switching on the 
field. Quantification of the heating power released by the particles was performed by the 
determination of the specific absorption rate (SAR, typically expressed in W/g of magnetic 





where C is the volume specific heat capacity of the sample (4185 J/LK for dilute aqueous 
suspensions), Vs = 0.5 mL is the sample volume, m is the mass of magnetic material (5 mg 
in all samples), and /dT dt  is the initial slope of the temperature vs. time curve. 
2.3. Cell Culture Assays 
Human embryonic kidney (HEK 293; ECACC no. 85120602), human cervix adeno-
carcinoma (HeLa; ECACC no. 93021013ATCC), and human liver carcinoma (HepG2; 
ECACC no. 85011430) cells were supplied by the Cell Culture Facility (University of Gra-
nada). Cell lines were grown at 37 °C in a 5% CO2 atmosphere in Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), 2 mM 
glutamine plus 100 U/mL penicillin and 0.1 mg/mL streptomycin. 
  
. f li i f li i ( , botto left) to the magnetite nanoparticles (bottom,
right). FA was reacted with N,N′-dicyclohexylcarbodiimide (EDC)/dimethyl formamide-pyridine
(DMF-Py), and the resulting anhydride was contacted with PEI-coated magnetite (top).
Particle size, shape, and EDX analyses were performed using a FEI-Titan (ThermoSci-
entific, Hillsboro, OR, USA) high-resolution trans ission electron microscope (HRTEM)
operated at 300 kV. Furthermore, hydrodynamic particle diameters were evaluated by dy-
namic light scattering in a Malvern Zeta Sizer NanoZS (Malvern Instruments, Malvern, UK).
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FTIR spectra were recorded at room temperature from powder using a PerkinElemer FT-IR
Spectrum Two. (Waltham, MA, USA) X-ray photoelectron spectroscopy (XPS) analysis of
the samples was performed in a Kratos Axis Ultra-DLD (Kratos Analytical, Manchester,
UK) XPS spectrometer using monochromatic Al Kα radiation and data were collected from
three spectra from a 300 µm × 700 µm area.
All particles described in this work demonstrated to be colloidally stable, with no
sedimentation for days after preparation. As an indication of the stability, we measured
the electrophoretic mobility using the above cited Malvern instrument. No attempt was
made to calculate the zeta potential because it lacks true significance when the parti-
cles are coated with polymers, as in our case [40]. A sufficiently high (roughly around
3 µm·s−1/V·cm−1) is a good indication of electrostatic repulsion between the particles
contributing to their stability.
Magnetic hyperthermia was applied to samples contained in 1.5 mL Eppendorf tubes,
which were located inside a coil (8 turns, 45 mm coil length, 20 mm inner diameter)
built with a copper tube of 6 mm inner diameter. Thermostatic water was circulated
through the tube during the experiment, in order to avoid interference of Joule heating
on the hyperthermia induced by the AMF. A Royer-type oscillator was used to produce
the alternating current applied to the coil for producing the AMF. The frequencies used
were 115, 135, 155, and 175 kHz, and the H field amplitude was 12 kA/m in all cases, as
determined with a NanoScience Laboratories Ltd. Probe (Keele, UK). The tube containing
the suspension (0.5 mL and 10 mg/mL particle concentration) was pre-thermostated to
the starting temperature of 30 ◦C and placed inside the coil. An optical fiber thermometer
(Optocon AG, Weidmann Technologies Deutschland GMBH, Dresden, Germany) was used
to measure the temperature of the sample at 3 s time intervals after switching on the
field. Quantification of the heating power released by the particles was performed by the
determination of the specific absorption rate (SAR, typically expressed in W/g of magnetic








where C is the volume specific heat capacity of the sample (4185 J/LK for dilute aqueous
suspensions), Vs = 0.5 mL is the sample volume, m is the mass of magnetic material (5 mg
in all samples), and dT/dt is the initial slope of the temperature vs. time curve.
2.3. Cell Culture Assays
Human embryonic kidney (HEK 293; ECACC no. 85120602), human cervix adenocar-
cinoma (HeLa; ECACC no. 93021013ATCC), and human liver carcinoma (HepG2; ECACC
no. 85011430) cells were supplied by the Cell Culture Facility (University of Granada). Cell
lines were grown at 37 ◦C in a 5% CO2 atmosphere in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), 2 mM glutamine plus
100 U/mL penicillin and 0.1 mg/mL streptomycin.
2.4. Hyperthermia Effects on Tested Cells
Adherent growing cells were trypsinized following standard procedures and resus-
pended in Krebs Henseleit Buffer containing 20 mM glucose at 5 × 105 cells/mL. FR
positive (HeLa, HepG2) and control (HEK 293) cells (2 × 105 cells) were incubated under
constant shaking with 75 or 150 µg/mL of the different compounds for 2 h at 37 ◦C. Then,
cells were subjected to MFHT (12 kA/m, 175 kHz) for 2 h, while maintaining a temperature
of 37 ◦C for cell growth. Cells kept in exactly the same conditions without the applica-
tion of the magnetic field were used as controls. To address the effects of hyperthermia,
cytotoxicity and clonogenic assays were performed.
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2.5. Cytotoxicity of Compounds
For cytotoxicity assays, 1 × 103 cells were seeded in 48-well plates in quadruplicate
immediately after magnetic field treatment and the cytotoxicity was assayed 48 h later by
determining the percentage of cell viability (with respect to unexposed cells) using the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) method, which
correlates the cellular metabolic activity with the number of viable cells in the culture.
Results are reported as % viability based on the untreated control cells at 48 h, normalized
to 100% viable.
2.6. Clonogenic Assay
To study the differences in the ability to generate clones between untreated and
treated cells, 1 × 103 cells were seeded in 6-well plates immediately after the magnetic field
treatment. After 72 h, cells were fixed with 2% (w/v) paraformaldehyde in PBS solution and
stained with 0.01% (w/v) of crystal violet for 30 min. The number of clones was measured
using ImageJ software (NIH).
2.7. Statistical Analysis of Cell Tests
Results were expressed as means ± 1 standard deviation. The statistical significance
of variations was evaluated using a two-way ANOVA. Post ANOVA pair comparison
between the means of each group was performed by means of the Tukey HSD test in order
to check for significantly different effects [43]. A p-value < 0.05 was considered significant.
3. Results and Discussion
3.1. Particle Characterization
We hypothesize that the one-pot solvothermal synthesis of MNPs from FeCl3·6H2O,
ethane-1,2-diol, sodium acetate, and the polyamine polymer PEI is a feasible approach to
obtain amino-decorated MNPs suitable for hyperthermia and for further functionalization.
In fact, the role of ethane-1,2-diol as a reducing agent and of sodium acetate as both an
electrostatic stabilizer (to prevent particle agglomeration) and a coadjuvant in the reduction
of FeCl3 is well established [37]. The use of PEI during the synthesis [34,35,44] or post-
synthesis [32,33,37] to yield MNPs bearing amino groups has already been reported.
Three different molecular weights of branched PEI were assayed to yield MPN-1 (PEI
1.8 kDa), MNP-2 (PEI 10 KDa), and MNP-3 (PEI 25 kDa) that, after exhaustive washing
with water, remained in suspension without sedimentation. The hydrodynamic diam-
eters of MNP-1, MNP-2, MNP-3, and MNP-4 were evaluated by DLS as 190 ± 50 nm,
160 ± 40 nm, 250 ± 140 nm, and 220 ± 60 nm, respectively, larger than the 85 nm reported
by Wang et al. [35] for similar particles obtained with PEI10K. In all cases, the coating of
the magnetite particles with PEI yielded highly stable systems, with visually no particle
settling even several days after preparation. As an indication of the role of electrostatic re-
pulsion between the particles on the observed stability, we determined their electrophoretic
mobility in water. No attempt was made to calculate the zeta potential, as the mere notion
of this quantity is not fully justified for particles coated with a polymer layer. The values
of the electrophoretic mobilities (determined always by triplicate, using 9 determinations
in each sample) were (in practical units of µm·s−1/V·cm−1): 2.528 ± 0.004, 2.738 ± 0.010,
3.339 ± 0.004, and 2.583 ± 0.005, for samples MNP-1, MNP-2, MNP-3, and MNP-4, re-
spectively. These values indicate that the particles experience sufficient repulsive forces to
account for their stability in addition to the steric repulsion associated to the polymer layer.
Samples MNP-1 and MNP-3 were further characterized by the high-resolution trans-
mission electron microscopy (HRTEM). Micrographs in Supplementary Information File
Figure S1 shows that the MNP-1 particles are more regular and better defined than those
of MNP-3, and that, although both samples show a selected area electron diffraction with
an interplanar spacing of 0.25 nm (consistent with that of (311) planes in magnetite [45]),
the crystallinity of MNP-1 is superior.
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The HRTEM also allowed the measurement of the lattice spacings of 0.45 nm and
0.30 nm for MNP-1 and 0.29 nm for MNP-3, compatible with the planes (111) and (220) of
magnetite (Figure S2). Since sample MNP-1 shows better magnetic parameters (see below)
and crystallinity, efforts were focused on its characterization. The size of the electron-dense
nuclei was estimated as 25 ± 6 nm, with 0.22 as the coefficient of variance (Figure S2), and
the HRTEM revealed the crystalline order of the particles (Figure 1a).
Polymers 2021, 13, x FOR PEER REVIEW 6 of 18 
 
 
each sample) were (in practical units of μm·s−1/V·cm−1): 2.528 ± 0.004, 2.738 ± 0.010, 3.339 ± 
0.004, and 2.583 ± 0.005, for samples MNP-1, MNP-2, MNP-3, and MNP-4, respectively. 
These values indicate that the particles experience sufficient repulsive forces to account 
for their stability in addition to the steric repulsion associated to the polymer layer. 
Samples MNP-1 and MNP-3 were further characterized by the high-resolution trans-
mission electron microscopy (HRTEM). Micrographs in Supplementary Information File 
Figure S1 shows that the MNP-1 particles are more regular and better defined than those 
of MNP-3, and that, although both samples show a selected area electron diffraction with 
an interplanar spacing of 0.25 nm (consistent with that of (311) planes in magnetite [45]), 
the crystallinity of MNP-1 is superior.  
The RTE  also allo ed the measurement of the lattice spacings of 0.45 nm and 0.30 
nm for MNP-1 and 0.29 nm for MNP-3, compatible with the planes (111) and (220) of 
magnetite (Figure S2). Since sample NP-1 shows better magnetic parameters (see below) 
and crystallinity, efforts were focused on its characterization. The size of the electron-
dense nuclei was estimated as 25 ± 6 nm, with 0.22 as the coefficient of variance (Figure 
S2), and the HRTEM revealed the crystalline order of the particles (Figure 1a). 
 
Figure 1. HRTEM (a) and high-angle annular dark-field (HAADF) images of MNP-1 (b), showing 
the distribution of Fe (c) and N (d) atoms. 
In order to gain additional insight into the distribution of Fe and N in the nanoparti-
cle, a high-angle annular dark-field imaging analysis was carried out, revealing that both 
Fe and N are uniformly distributed over the nanoparticle, with Fe forming the core, and 
N appearing grouped into spots on the surface (Figure 1b–d and Figure S3). These results 
suggest that the incorporation of PEI to the MNPs does not disrupt the crystal lattice of 
the magnetite, and that the amino groups are arranged as a set of patches on the surface. 
Figure 1. HRTE (a) and high-angle annular dark-field (HAADF) i ages of NP-1 (b), showing
the distribution of Fe (c) and N (d) atoms.
In order to gain ad itional insight into the distribution of Fe and N in the na oparticle,
a high-angle annular d rk-field imaging a alysis was c rried out, revealing that both Fe
and N are uniformly distributed over the nanoparticle, with Fe forming the core, and N
appearing grouped into spots on the surface (Figure 1b–d and Figure S3). These results
suggest that the incorporation of PEI to the MNPs does not disrupt the crystal lattice of the
magnetite, and that e amino gr ups are ar anged as a set of patches on the surface.
The full scan XPS spectra (Figure S4, Table S1) present peaks at 56 eV, 285 eV, 399 eV,
530 eV, and 711 eV which are attributed to Fe3p, C1s, N1s, O1s, and Fe2p, respectively,
confirming the incorporation of PEI and allowing the quantification of the elements present
in the MNPs. The influence of the size of PEI on the composition of MNPs becomes apparent
when the elemental analysis by the XPS is normalized by the abundance of Fe. Thus, the
[O]:[Fe] and [C]:[Fe] ratios increase as the molecular weight of PEI becomes larger, whereas
the [N]:[Fe] ratio for PEI10K and PEI25K remains very similar and twofold higher than that
for PEI2K (Figure 2). The high resolution Fe2p spectra (Figure S5) present two major peaks
at 710 eV and 723 eV, corresponding to Fe2p3/2 and Fe2p1/2, respectively [46]. The Fe2p3/2
signal was fitted with two peaks at 709.7 eV and 711.0 eV that are consistent with the
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literature values for magnetite Fe2+2p3/2 and Fe3+2p3/2 [40]. The O1s spectra (Figure S5)
were fitted with three peaks centered at 529.4 eV, 531.2 eV, and 533.3 eV, assigned to Fe–O,
hydroxide, or defective oxide and organic oxide, respectively [47]. The high resolution C1s
spectra (Figure S6) can be fitted with three peaks at 284.7 eV, 285.5 eV, and 288.5 eV that are
assigned to C–C, C–N, and C = O, respectively, and the N1s signal centered at 399 eV was
fitted with two peaks separated by 1.2 eV, pointing to the existence of N in two different
environments [48].
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Figure 2. Relationship between the molecular weight of PEI and the relative atomic concentration
of N (grey, o pattern), C (gr en, h rizontal pattern), and O (cyan, ver ical pattern). Values are
normalized by the atomic concentration of Fe. The values of the normalized concentrations are
indicated for clarity in performing a quantitative comparison.
3.2. Magnetic Proper es and Magnetic Field Hyperthermia (MFHT)
In order to evaluate their pplication in MFHT, a magnetic hysteresis inv stigation
was first performed. The r sults are hown in Figure 3, and demo strate that all samples
have superparamagnetic behavior, with no hysteresis. The saturation mass magnetizatio
was estimated as 68.9 emu/g for MNP-1, 63.3 emu/g for MNP-2, and 62.7 emu/g for
MNP-3. On the whole, these values are comparable to the highest val es re orted for
magnetic nanospheres in, for instance, [49]. Since, as evidenced by Figure 3, the saturation
of magnetization takes place for field strengths H ∼= 798 kA/m, and the experimental
data on hyperthermia are acquired at much lower fields of 12 kA/m so that saturation is
never reached, we may wonder what the significance of the reported MS data for magnetic
hyperthermia is. In fact, the major hysteresis cycle would not be involved in power
dissipation. Even the minor loop, also shown in Figure 3, can be neglected, as the coercivity
observed is almost zero. As stated by Dennis and Ivkov [11], strict superparamagnetic
behavior is undesirable for heat release. We also note that the hysteresis cycle is obtained
at static conditions, while MFHT requires over 100 kHz ac fields. This leads us to consider
the physics behind magnetic hyperthermia, and, first of all, the characteristic times for
spontaneous magnetization inversion, driven by thermal fluctuations. Such a time scale
must be short as compared with the measurement time, that is, about 10 µs; if this duration
is shorter than the inverted one, the magnetic moment will apparently remain fixed between
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successive applied field inversions, leading to finite coercivity and remanence, hence to a
finite area hysteresis cycle now leading to heating power release.
Polymers 2021, 13, x FOR PEER REVIEW 8 of 18 
 
 
nanospheres in, for instance, [49]. Since, as evidenced by Figure 3, the saturation of mag-
netization takes place for field strengths H ≅ 798 kA/m, and the experimental data on hy-
perthermia are acquired at much lower fields of 12 kA/m so that saturation is never 
reached, we may wonder what the significance of the reported MS data for magnetic hy-
perthermia is. In fact, the major hysteresis cycle would not be involved in power dissipa-
tion. Even the minor loop, also shown in Figure 3, can be neglected, as the coercivity ob-
served is almost zero. As stated by Dennis and Ivkov [11], strict superparamagnetic be-
havior is undesirable for heat release. We also note that the hysteresis cycle is obtained at 
static conditions, while MFHT requires over 100 kHz ac fields. This leads us to consider 
the physics behind magnetic hyperthermia, and, first of all, the characteristic times for 
spontaneous magnetization inversion, driven by thermal fluctuations. Such a time scale 
must be short as compared with the measurement time, that is, about 10 μs; if this duration 
is shorter than the inverted one, the magnetic moment will apparently remain fixed be-
tween successive applied field inversions, leading to finite coercivity and remanence, 
hence to a finite area hysteresis cycle now leading to heating power release. 
 
Figure 3. Magnetization cycles of samples MNP-1, MNP-2, MNP-3, and MNP-4. Insets: Low-field regions. 
The most widely used approach for estimating the characteristic time of a given par-
ticle is the so-called linear response theory, originally proposed by Rosensweig [50]. It is 
assumed that the magnetization depends linearly on the field (this means low strength of 
the applied ac field), through a complex magnetic susceptibility, its imaginary component 
Figure 3. Magnetization cycles of samples MNP-1, MNP-2, MNP-3, and MNP-4. Insets: Low-field regions.
The most widely used approach for estimating the characteristic time of a given
particle is the so-called linear response theory, originally proposed by Rosensweig [50]. It is
assumed that the magnetization depends linearly on the field (this means low strength of
the applied ac field), through a complex magnetic susceptibility, its imaginary component
being associated to the finite time required for the magnetization to be reversed under the
field oscillations. Two mechanisms are admitted for the magnetization relaxation: one is
the so-called Brownian relaxation, in which the magnetization changes because the whole
particle rotates inside the viscous liquid (viscosity ηm) where it is suspended; the second
one, the Néel relaxation, corresponds to the inversion of magnetization inside the fixed











Ke f f VM
exp




where VH(VM) is the hydrodynamic (magnetic) volume of the particle, τA is a characteristic
(attempt) time (taken in the order of 10−9 s), and Ke f f is the anisotropy energy density,
related to the saturation magnetization and the anisotropy field (Hk: the anisotropy field,
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, Msat being the volume saturation magnetization). In the case of magnetite,
Keff ∼= 25 kJ/m3, Hk ∼= 0.14 T, and for particles with 200 nm diameter, the relaxation times
fulfill the condition τB = 2.8 ms <<τN . According to the linear response model, an average
relaxation time can be calculated as τ = (τBτN)/(τB + τN) ≈ τB, and if the frequency f of
the field is below the critical value 2π f τB = 1 (or f < 60 Hz), the randomization by the
thermal inversion of the particle orientation (taking a shorter time than the measurement
field period) will dominate the behavior and no net magnetization will be produced, thus
no power dissipation.
If only the Brownian relaxation could be invoked for heating by ac magnetic fields,
the power release would roughly depend only on the size of the paramagnetic particle and
its viscous friction with the medium. Since this is not the case, and there is a tremendous
variability in SAR values [51], more factors must be considered, the most important of
which is anisotropy (including magnetic, shape, or aggregation). In fact, the power released
is found to increase with the saturation magnetization and with Ke f f . This gives us clues
on the ways to increase the hyperthermia response [11].
Figure 4 shows the temperature variation of suspensions containing 10 mg/mL of
magnetic nanoparticles with time of application of a 12 kA/m AMF of frequencies between
115 kHz and 175 kHz, which are below the safety limits of H × f < 485 kA/m.kHz [52], and
within the range of those used by the few existing commercial devices. After 30 s at 175 kHz
the temperature reached 51.6 ◦C, 41.1 ◦C, and 50.0 ◦C for MNP-1, MNP-2, and MNP-3,
respectively (Figure 4), indicating a good performance in hyperthermia. This suggests
that MNP-1 is the best candidate for MFHT applications. Interestingly, MNP-1 is the
sample showing the largest magnetic saturation (Figure 3), in accordance with theoretical
predictions. Quantification of the hyperthermia performance can be done through SAR
calculations, as displayed in Table 1. Although all samples perform similarly, MNP-1 yields
slightly better values. On the whole, the SAR obtained ranges above the average of the
values reported in a systematic investigation using 30 types of IONPs by Lanier et al. [51],
and it is comparable to that reported by Mohapatra et al. [49] f or spheres.
Table 1. SAR values of the MFHT of the samples investigated. The uncertainties correspond to 95%
confidence intervals in the slopes and the SAR.
Sample Frequency dT/dt (◦C/s) SAR (W/g)
MNP-1
115 0.48 ± 0.03 200 ± 12
135 0.56 ± 0.04 233 ± 17
155 0.67 ± 0.03 279 ± 13
175 0.80 ±0.04 330 ± 17
MNP-2
115 0.38 ± 0.03 157 ± 12
135 0.448 ± 0.026 186 ± 11
155 0.48 ± 0.04 200 ± 17
175 0.58 ± 0.04 239 ± 16
MNP-3
115 0.45 ± 0.03 187 ± 12
135 0.58 ± 0.04 242 ± 17
155 0.63 ± 0.04 261 ± 17
175 0.72 ± 0.04 299 ± 17
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3.3. Functionalization of MNP-1
One of the major challenges for the clinical use of MFHT is to achieve a significant
and homogeneous temperature increase at the tumor while the surrounding tissue re-
mains unaltered. The existence of a strong correlation between tumor size, temperature
enhancement, and SAR has guided the synthesis of MNPs with improved SAR values [52].
However, the increase of temperature is also dependent on the concentration of the MNPs
in the tumor tissue, and in consequence, the MNPs have been functionalized with different
ligands to promote specific interactions with the target cells, with the aim of delivering and
concentrating the MNPs at the site of action. As mentioned, FR is overexpressed in many
cancers and this has been exploited for active cancer targeting, hence FA was selected as
the ligand to functionalize MNP-1. In fact, examples of functionalization of MNPs with FA
either by ionic interactions [26] or by covalent bonds by complex procedures, including
click chemistry [22] and reductive amination [20] or coupling chemistry [21,23–25,27,28],
can be found in the literature. Recall that the surface of MNP-1 shows patches with N
(Figure 1d), which according to the 1 Ns XPS spectra, correspond to amino groups (Figure
S6). Since FA presents two carboxylic groups that can be transformed into an anhydride
group [28], we envisioned the reaction of the folic acid anhydride with MNP-1 to form an
amide linkage as a straightforward strategy for the covalent functionalization of MNP-1
with folic acid to yield MNP-4. FTIR spectrum of MNP-4 presents signals at 1640 cm−1,
1606 cm−1, and 1530 cm−1 that correspond to amide I band, C = O stretching of the car-
boxylate, and amide II band, respectively (Figure 5). These features are in agreement with
the reaction of MNP-1 with folic anhydride to produce amide groups with the concomitant
formation of carboxylate groups. The saturation mass magnetization was estimated as
60.6 emu/g for MNP-4, which is slightly lower than the 68.9 emu/g estimated for MNP-1
(Figure 3), as expected from the coating with a significant layer of nonmagnetic material.




Figure 5. FTIR of MNP-1 (blue) and after reaction with folic anhydride to yield MNP-4 (red). Inset: 
detail of the significant peaks in the C = O stretching region. 
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3.4. In Vitro Cell Viability Essays
Although the MNPs have been reported to be well tolerated by cells [53], high levels
of iron are known to promote reactive oxygen species (ROS) via Fenton reaction, leading
to ferroptosis, including lipid peroxidation, DNA damage, and cell death [54,55]. Indeed,
concentrations as high as 31.36 mg of Fe/cm3 in tumors have been administrated intratu-
morally in patients with glioblastoma [56], but this mode of administration is not practical
for metastasis, or large and/or poorly defined tumors. Intravenous administration is the
most versatile method, the main challenge being the accumulation of the MNPs within
the tumor. Feraheme® (AMG pharmaceutical, Waltham, MA, USA) is among the FDA
approved iron nanoparticle drugs that have been safely administrated in larger quantities,
the recommended dose being 510 mg of iron [57]. In this context, the toxicity of MNP-1 and
MNP-4 was evaluated against three cell lines that express different levels of FR, including
the low-FR expressing HEK cells and the high-expressing FR HeLa and HepG2 cells [58,59].
The maximum concentration assayed was 150 µg MNPs/mL culture, which is within the
range of the concentration of Fe in blood after administration of the recommended dose of
Feraheme®, considering a 5 L blood volume.
Figure 6 shows that, in general, MNP-1 and MNP-4 present a moderate cytotoxicity,
the former being more toxic than the latter, in full agreement with the reported higher
toxicity of positively charged nanoparticles [60]. The results obtained after 24 h (A) and
48 h (B) are very similar. This is in accordance with most studies in the literature, where
the cytotoxicity tests are typically extended to 48 h at most [26,61–64].
An evaluation of the interest of MNP-4 in MFHT was carried out at a concentra-
tion of 150 µg/mL on HEK (low FR overexpression), HeLa, and HepG2 cells (high FR
overexpression) in a magnetic field of 12 kA/m and a frequency of 175 kHz, which, as
mentioned, are reasonable parameters that are comparable to those used in the medical
AMF devices (100 kHz and maximum of 15 kA/m, according to Magforce AG specifications
(https://www.magforce.com/home/ Accessed on: 13 May 2021), and to those reported
in most investigations [45]. Results are summarized in Figure 7, and as expected from
the cytotoxicity evaluation, in the absence of a magnetic field, neither MNP-1 nor MNP-4
produce any significant cell toxicity or decrease in the capability to form colonies. The
scenario changed when a magnetic field was applied, the effect on cell viability and colony
formation being dependent on the expression of FR. Thus, whereas the effect of MNP-1
is independent on the field, the action of MNP-4 is dependent on both the expression of
FR and the magnetic field. These results support the potential of MNP-4 in MFHT at a
concentration in the range of that approved by FDA for iron nanoparticle drugs since the
cell viability and clone formation suffer a significant reduction in those cells expressing
high levels of FR whereas the FR negative cells remain unaffected.
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Figure 6. Cytotoxicity assays of MNP-1 and MNP-4 against HEK, HeLa, and HepG2 cells, incubated
with increasing concentrations of the MNPs for 24 h. Results are means ± 1 standard deviation
(n = 6). * p < 0.05 vs. control cells (incubated in the absence of nanoparticles). (A): 24 h incubation
time; (B): 48 h.
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4. Conclusions
We have demonstrated that the one-pot solvothermal synthesis of magnetic nanoparti-
cles (MNPs) from FeCl3·6H2O, sodium acetate, and ethane-1,2-diol in presence of polyamine
polymer PEI is a reliable method to produce MNPs with amino groups on the surface,
preserving the magnetite crystal lattice and allowing the coupling of different functions
without any previous derivatization. It is interesting to mention that the method proposed
provides, in a single stage, magnetite nanoparticles coated with PEI in a stable manner,
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which is probably advantageous over methods based on the post-synthesis addition of PEI
on already formed particles, often requiring repeated layer-by-layer stages.
Particles synthesized with PEI of three different molecular weights are all found to be
superparamagnetic, with a magnetization saturation above 60 emu/g, which is comparable
or higher than the values reported for spherical nanoparticles and make them attractive
for MFHT. Studies performed for field frequencies 115, 135, 155, and 175 kHz and field
strength H = 12 kA/m found that the heating power released ranges between 180 and
330 W/g, which is on the high side of reported values for these kinds of particles, and
that PEI 1.8 kDa is the most suitable polyamine (sample MNP-1). Although larger rates
of heat release have been reported, it must be mentioned that the real application of these
particles in hyperthermia is not just based on rapid heating, but also on the reliability of
their production, size, and the magnetic properties, control, and biocompatibility of the
final magnetic nanostructure.
In addition, the particles are designed as elements of a so-called targeted thermal
therapy. The combination of MNP-1 with folic anhydride yields folic acid-functionalized
nanoparticles MNP-4. In vitro cellular assays at a concentration in the range of that ap-
proved by FDA for iron nanoparticle drugs and conditions and a magnetic field comparable
to those used in the medical AMF devices reveals that those cell lines with high levels of
overexpression of FR are selectively damaged by MNP-4 in the presence of the magnetic
field, whereas those with a low level of expression of FR remain unaltered, supporting fur-
ther evaluation of MNP-4 on animal models. This is the expected continuation of this work,
as the in vivo use of these particles will be the determinant for upgrading the synthesized
nanostructures to therapeutic tools against cancer. They might furthermore become multi-
objective tools if they can be also used as antitumor drug vehicles, whereby the thermal
and chemical therapies can be applied at the same time in a target-selected fashion.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/polym13101599/s1, Figure S1: Dark field transmission electron microscopy image (a) and
selected area electron diffraction (b) of MNP-1 (1) and MNP-3 (2). Figure S2: High resolution
transmission electron microscopy image (a) and selected area electron diffraction (b) of MNP-1 (1)
and MNP-3 (2). Figure S3: High-angle annular dark-field (HAADF) images of MNP-1 showing the
distribution of Fe (a), N (b), Fe and N (c), and H (d) atoms. Figure S4: XPS spectra of samples (from
bottom to top) MNP-1(blue), MNP-2(red), and MNP-3(black). Figure S5: High-resolution XPS spectra
of Fe2p (a) and O1s (b) of MPN-1 (1), MNP-2 (2) and MNP-3 (3). Experimental data are shown in
light blue, envelope in blue, and residuals (on top) in brown. Figure S6: High-resolution XPS spectra
of C1s (a) and N1s1s (b) of MPN-1 (1), MNP-2 (2) and MNP-3 (3). Experimental data are shown in
light blue, envelope in blue, and residuals (on top) in dark red. Table S1: Quantification (% atomic
concentration) by XPS of the most significant peaks detected in MNP-1, MNP-2 and MNP-3.
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